Drug interactions with itraconazole, fluconazole, and terbinafine and their management - 07/09/11
Correspondence: Aditya K. Gupta, MD, FRCPC, 490 Wonderland Rd South, Suite 6, London, Ontario, N6K 1L6, Canada. E-mail: agupta@execulink.com.
Abstract |
A drug interaction develops when the effect of a drug is increased or decreased or when a new effect is produced by the prior, concurrent, or subsequent administration of the other. Before prescribing a drug, it is important to obtain a thorough drug history of the prescription and nonprescription medications taken by the patient. The nonprescription medications may include items such as nutritional supplements and herbal medications. The risk of side effects is an inevitable consequence of drug use. The frequency of adverse reactions is increased in those patients receiving multiple medications. Drug interactions reported in animal or in vitro studies may not necessarily develop in humans. When drug interactions are observed with a particular agent, it cannot be automatically assumed that all closely related drugs will necessarily produce the same interaction. However, caution is advised until sufficient experience accrues. The prescriber should not overestimate or underestimate the potential for a given drug interaction on the basis of personal experience alone. Drug interactions will not necessarily occur in every patient who is given a particular combination of drugs known to produce an interaction. For a clinically significant drug interaction to be manifest, several other factors may be relevant other than just using the two drugs. In many instances drug interactions can be predicted and therefore avoided if the pharmacodynamic effects, the pharmacokinetic properties, and the mechanisms of action of the 2 drugs in question are known. In the case of contraindicated drugs, it may be possible to use an alternative agent. (J Am Acad Dermatol 1999;41:237-49.)
Le texte complet de cet article est disponible en PDF.Plan
From the Division of Dermatology, Department of Medicine, Sunnybrook and Women’s Health Science Center (Sunnybrook site) and the University of Toronto Medical School, Torontoa; the Department of Dermatology, University of Minnesota, Minneapolisb; and the Division of Clinical Pharmacology, Department of Medicine and Department of Pharmacology, Sunnybrook and Women’s Health Science Center (Sunnybrook site) and the University of Toronto Medical School, Toronto.c |
|
Reprints are not available from the authors. |
|
0190-9622/99/$8.00 + 0 16/1/97351 |
Vol 41 - N° 2
P. 237-249 - août 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?